NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
02/13/2024
Back to search
Official data from USPTO
ALCANZA
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: US
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
26
Latest update
02/13/2024
Classification
Registered
Trademark type
Word
Nice classes
42
Filing date
04/08/2022
Registration date
02/13/2024
Expiration date
-
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Complete case details
Structured fields from the responsible authority and the official record.
Status date
02/13/2024
Last transaction
02/13/2024
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
06/30/2022
First use in commerce
06/30/2022
Drawing code
4
Owner type
16
Owner location
Lake Mary, FL, US
Examiner
LEVINE, HOWARD B
Law office
M60
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
Alcanza Clinical Research, LLC
Alcanza Clinical Research, LLC
Representatives
Mark A. Wright MCLANE MIDDLETON, PROFESSIONAL ASSOCIATION
Technical classification
Nice Classes
Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 42
scientific research in the field of health care; clinical medical research; medical and scientific research, namely, conducting clinical trials for others; scientific research in the nature of conducting clinical trials for others; clinical medical and scientific research in the form of clinical trials of drugs for third party manufacturers; clinical scientific research in the form of clinical trials of drugs for third party manufacturers; laboratory research in the field of pharmaceuticals
Publications
History of USPTO decisions and trademark events.
26 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
02/13/2024
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
01/12/2024
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
01/11/2024
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
12/15/2023
SUPC
STATEMENT OF USE PROCESSING COMPLETE
12/14/2023
EX1G
SOU EXTENSION 1 GRANTED
12/14/2023
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
12/13/2023
IUAF
USE AMENDMENT FILED
12/05/2023
EXT1
SOU EXTENSION 1 FILED
12/05/2023
EEXT
SOU TEAS EXTENSION RECEIVED
12/05/2023
EISU
TEAS STATEMENT OF USE RECEIVED
12/05/2023
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
06/06/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
04/11/2023
PUBO
PUBLISHED FOR OPPOSITION
04/11/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
03/22/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
03/08/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
03/07/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
03/07/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
03/07/2023
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
01/26/2023
GNRT
NON-FINAL ACTION E-MAILED
01/26/2023
CNRT
NON-FINAL ACTION WRITTEN
01/26/2023
DOCK
ASSIGNED TO EXAMINER
01/26/2023
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
04/12/2022
NWAP
NEW APPLICATION ENTERED
04/12/2022
Continuous trademark protection
Get notified about every new filing that threatens ALCANZA or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.